Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., March 03, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a ...

A panelist discusses how a 67-year-old male smoker presented with frequent headache and dizziness but had an otherwise unremarkable medical history with no splenomegaly.

Polycythemia Vera is a rare disorder marked by a continuous rise in the number of red blood cells in the blood, with an accompanying increase in white blood cells and platelets. It is the most ...

Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...

Polycythemia vera (PV) is a blood cancer that begins in the marrow of your bones, the soft center where new blood cells grow. It causes your marrow to make too many red blood cells so your blood ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...